Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Evaluation of targeting c-Src by the RGT-containing peptide as a novel antithrombotic strategy

Fig. 4

Myr-AC ~ CRGT peptide per se did not directly alter the activity of c-Src. a Effect of myr-AC ~ CRGT on c-Src activity in platelets. The peptide-pretreated platelets were lysed and blotted for Src-pY416, Src-pY527, Src or β3. The band intensity was quantified using the NIH Image J software. The extent of Src Y416 or Y527phosphorylation was expressed as a ratio of Src-pY416 or Src-pY527 signals versus total Src signals. Integrin β3 served as a loading control. b Effect of myr-AC ~ CRGT on the interaction of integrin β3 with c-Src or Csk. The peptide-pretreated platelets were lysed and immunoprecipitated with anti-β3 antibody and then analyzed with anti-β3, anti-Src, and anti-Csk antibodies. c Densitometric presentations of the results in panel b. d Effect of myr-AC ~ CRGT on the interaction of c-Src with integrin β3 or Csk. e Densitometric presentations of the results in panel d. Results are shown the mean and SD of three independent experiments. f Substrate peptide KVEKIGEGTYGVVYK was mixed with purified active c-Src in the presence or absence of the CRGT, CGRT peptides, or PP2 and then the [γ-32P]ATP incorporation was measured. Data are shown as the mean and SD of three independent experiments

Back to article page